Results 81 to 90 of about 28,065 (211)
ABSTRACT Severe malaria remains a major cause of acute kidney injury and multiorgan failure in endemic regions, often requiring renal replacement therapy. However, access to dialysis is limited in many resource‐constrained settings, making outcomes highly dependent on early diagnosis and effective antimalarial treatment. We report a 32‐year‐old man who
Tamirat Godebo Woyimo +8 more
wiley +1 more source
Residual Chemical Shift Anisotropies in the Structure Determination of Small Molecules
Plasma neutrophil elastase(ELANE) was markedly elevated in patients with alcohol use disorder, indicating a dysregulated protease‐antiprotease inflammatory balance characterised by decreased SERPINA3. ELANE showed excellent diagnostic specificity(AUC = 0.8683), supporting its potential utility as a neuroinflammatory biomarker for AUD.
Nilamoni Nath +3 more
wiley +1 more source
BQ123 effects on survival in convalescent mice after artemether treatment.
Despite successful Artemether treatment, mortality remains high in PbA-infected mice. BQ123 adjunctive treatment, in combination with artemether, however, significantly improved survival in PbA mice; Log-rank (Mantel-Cox) test; * = p < 0.05.
Oscar B. Akide-Ndunge (2584441) +7 more
core +1 more source
Periods and therapeutic doses of artemether during complicated malaria.
Periods and therapeutic doses of artemether during complicated malaria.
Tite Minga Mikobi (13919530) +3 more
core +1 more source
Changes in the visceral functions of Plasmodium berghei-infected and-uninfected rats following administration of artemether. [PDF]
The effects of artemether (12.5, 25.0 and 50.0 mg/kg per day, i.m.), administered to different groups of Plasmodium berghei‐infected and ‐uninfected adult Wistar rats for 1 week, were investigated.
Iwalewa, E. O. +5 more
core +1 more source
The stumbling block for the continued, single-drug use of praziquantel (PZQ) against schistosomiasis is less justified by the risk of drug resistance than by the fact that this drug is inactive against juvenal parasites, which will mature and start egg ...
Robert Bergquist, Hala Elmorshedy
doaj +1 more source
Artemether: Entity of the Month
November's entity of the month at ChEBI is the antimalarial drug Artemether.
Duncan Hull
core +1 more source
U87 cells were treated with artemether of 300 µmol/L, shRNA transfected or treated with both. Serum free L-DMEM served as a negative control. Expressions of MMP-2/9 were checked with Western Blot.
Yi Hu (58993) +7 more
core +1 more source
The HSP90/Akt pathway may mediate artemether‐induced apoptosis of Cal27 cells
Tongue squamous cell carcinoma is the most common malignant tumor in oral and maxillofacial regions. Recent research has found that artemether can inhibit growth and induce apoptosis of cancer cells, although the mechanism is not clear. The present study
Jianhua Wu +5 more
doaj +1 more source
Streamlined Process for the Conversion of Artemisinin to Artemether
We report an improvement to the previously published manufacturing process for artemether, a key antimalarial drug, utilizing readily available reagents, easily controlled manufacturing conditions, and a greatly simplified workup and isolation.
David S. Teager (2082712) +1 more
core +1 more source

